 The European Commission EC has granted conditional approval to Incyte Corporation NASDAQ: INCY - MorphoSys AGs NASDAQ: MOR Minjuvi tafasitamab for relapsed or refractory diffuse large B-cell lymphoma DLBCL. The approval covers Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy, for DLBCL patients who are not eligible for autologous stem cell transplant ASCT. 